

Living FRIendly Summaries of the Body of Evidence using Epistemonikos (FRISBEE)

Medwave 2017 Nov-Dic;17(9):e7117 doi: 10.5867/medwave.2017.09.7117

Is pre-exposure prophylaxis effective for preventing HIV infection in men who have sex with men?

Authors: Rubén Allende[1,2], María Paz Acuña[2,3]

Affiliation:

[1] Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile

[2] Proyecto Epistemonikos, Santiago, Chile

[3] Departamento de Infectología, Hospital Dr. Sótero del Río, Santiago, Chile

E-mail: doctorapazacuna@qmail.com

Citation: Allende R, Acuña M. Is pre-exposure prophylaxis effective for preventing HIV infection in men who have sex with men?. *Medwave* 2017 Nov-Dic;17(9):e7117 doi:

10.5867/medwave.2017.09.7117 Submission date: 18/12/2017

Acceptance date: 27/12/2017

Publication date: 27/12/2017

Origin: This article is a product of the Evidence Synthesis Project of Epistemonikos Fundation, in collaboration with Medwave for its publication.

Type of review: Non-blinded peer review by members of the methodological team of Epistemonikos Evidence Synthesis Project

Abstract

INTRODUCTION

Increasing rates of HIV infection remain of concern, especially for high-risk groups such as men who have sex with men. Oral pre-exposure prophylaxis has emerged as an alternative to prevention. However, doubts persist in patients and physicians about its effectiveness.

METHODS

To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.

RESULTS AND CONCLUSIONS

We identified six systematic reviews including twelve studies overall, of which six were randomized trials. We concluded the use of oral pre-exposure prophylaxis reduces the probability of HIV infection in men who have sex with men, has few or no adverse effects, and is a measure with a good balance between benefits, risks and costs.

Problem

Despite increased community awareness, HIV infection rates continue to rise. One of the high-risk group is men who have sex with men, so better prevention strategies are required. The use of antiretroviral drugs in uninfected individuals, or pre-exposure prophylaxis (PrEP), has emerged as a promising tool for prevention in individuals at high risk of HIV infection. The most commonly used combination of PrEP has been oral emtricitabine with tenofovir disoproxil fumarate, and to a lesser extent tenofovir disoproxil fumarate alone. Despite the approval of the first as PrEP by the FDA in 2012, physicians and patients still question the effectiveness and safety of this measure.

Methods

To answer the question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others, to identify systematic reviews and their included primary studies. We extracted data from the identified reviews and



reanalyzed data from primary studies included in those reviews. With this information, we generated a structured summary denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos) using a preestablished format, which includes key messages, a summary of the body of evidence (presented as an evidence matrix in Epistemonikos), meta-analysis of the total of studies when it is possible, a summary of findings table following the GRADE approach and a table of other considerations for decision-making.

Key messages

• Pre-exposure prophylaxis reduces HIV infection in men who have sex with men, with minimal or no adverse effects.

About the body of evidence for this question

What is the evidence. See evidence matrix in Epistemonikos later	We found six systematic reviews [1],[2],[3],[4],[5],[6] that included 12 primary studies reported in 23 references [7],[8],[9],[10],[11], [12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25], [26],[27],[28],[29]. Six corresponded to randomized controlled trials reported in 17 references [7],[8],[11],[14],[15],[16],[18],[19],[20], [21],[23],[24],[25],[26],[27],[28],[29]. This table and the summary in general are based on the latter, given that observational studies did not increase the certainty of the existing evidence, nor did they provide relevant additional information.
What types of patients were included*	The patients included in the trials were HIV uninfected men who have sex with men, over 18 years of age, and considered at high risk of HIV infection (due to a history of high number of sexual partners, sexual intercourse without condom use, sex with people with sexually transmitted diseases, or sex in exchange for money).
What types of interventions were included*	All trials evaluated the use of oral PrEP in conjunction with standard prevention (including education and provision of condoms). Five evaluated the use of emtricitabine/tenofovir [11],[14],[20], [23], [29] and one the use of tenofovir alone [25]. Five trials evaluated against placebo [11],[14],[23],[25],[29] and three against a non-treatment group [14],[20],[25]. Five used PrEP on a daily basis [11],[14],[20],[25],[29] and one intermittently, before and after having sex [23]. One trial used behavioral therapy as a co-intervention [14] and one trial was pragmatic and open-label [20]. One trial included a small group of women [29], but since the vast majority of the participants were men who had sex with men, it was included in the analysis.
What types of outcomes were measured	The main outcomes analyzed were the rate of HIV infection and adverse effects. Qualitatively analyzed outcomes included changes in risk behaviors, mainly condom use objectified by interviews [14],[25] or indirectly by incidence of other sexually transmitted diseases [20]. The average follow-up of the trials was 15 months, with a range between 4 and 33 months.

* The information about primary studies is extracted from the systematic reviews identified, unless otherwise specified.



Summary of Findings

The information on the effects of oral PrEP in men who have sex with men is based on six trials [11],[14],[20],[23],[25],[29] which included 3974 patients.

It was not possible to extract enough information from the reviews identified to reconstruct the metaanalysis of HIV incidence. Therefore, the information presented is based on the results of the metaanalysis of a systematic review [1] that is based on four trials [11],[23],[25],[29] that included 3371 patients.

The information on adverse events is based on three trials [11],[14],[25] whose data were reusable from systematic reviews and included 2957 patients. The information on changes in condom use is based on three trials [14],[20],[25] that compared against no treatment, whose data were described qualitatively in the systematic reviews and included 1003 patients.

The summary of findings is as follows:

- Pre-exposure prophylaxis reduces HIV infection in men who have sex with men. The certainty of the evidence is high.
- Pre-exposure prophylaxis reduces leads to minimal or no increase in adverse effects. The certainty of the evidence is high.
- Pre-exposure prophylaxis might result in little or no difference in terms of condom use in men who have sex with men. The certainty of the evidence is low.



Patients Intervention Comparison	HIV uninfected men who have sex with men Oral pre-exposure prophylaxis (PrEP) Placebo or no treatment					
Outcome	Absolute effec					
	WITHOUT Oral PrEP	WITH Oral PrEP	Relative effect (95% CI)	Certainty of evidence (GRADE)		
	Difference: patients per 1000					
HIV incidence	50 per 1000	17 per 1000	RR 0.34			
	Difference: 33 (Margin of error: 10 less	(0.15 to 0.80)	⊕⊕⊕⊕ High			
Adverse effects	63 per 1000	72 per 1000	RR 1.14			
	Difference: 9 m (Margin of error: 18 less	(0.71 to 1.83)	⊕⊕⊕⊕ High			
Condom use	No differences between treat patients		⊕⊕OO ^{1,2} Low			
RR: Risk ratio. MD: Mean differe GRADE: Evidence *The risk WITH WITH Oral PrEI error). ¹ One level of cert indirect evidence	95% confidence interval (CI). e grades of the GRADE Working Gro OUT Oral PrEP is based on the risl (and its margin of error) is calcul- cainty of evidence was decreased d for the outcome. cainty of evidence was decreased d	k in the control group ated from relative eff ue to the use of non-	ect (and its m validated mea	argin of surements as		

Follow the link to access the interactive version of this table (Interactive Summary of Findings - iSoF)

About the certainty of the evidence (GRADE)*

$\oplus \oplus \oplus \oplus$

High: This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different⁺ is low.

 $\Theta \Theta \Theta O$

Moderate: This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different⁺ is moderate

$\oplus \oplus \bigcirc \bigcirc$

Low: This research provides some indication of the likely effect. However, the likelihood that it will be substantially different⁺ is high.

0000

Very low: This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different⁺ is very high.

*This concept is also called 'quality of the evidence' or 'confidence in effect estimates'.

+ Substantially different = a large enough difference that it might affect a decision.



Other considerations for decision-making

To whom this evidence does and does not apply

• These results apply to the use of emtricitabine/tenofovir as PrEP in men who have sex with men. It is reasonable to extrapolate these results to transgender women who have sex with men and sex workers, who were not explicitly included in the studies. This evidence does not apply as clearly to the use of tenofovir as monotherapy, given the low representation of this intervention in the trials. It does not apply to HIV uninfected men who have a serodiscordant stable male partner, since in this case it is more effective to treat the infected patient and achieve undetectable viral load to reduce HIV transmission than the use of PrEP.

About the outcomes included in this summary

• The selected outcomes are those considered critical for decision-making, based on the opinion of the authors of this summary. They agree with those presented in most systematic reviews identified.

Balance between benefits and risks, and certainty of the evidence

• Because it is an intervention with clear benefits and minimal to no adverse effects, the balance between benefits and risks is clearly favorable.

Resource considerations

- Tenofovir disoproxil fumarate costs between 2 and 5 dollars per pill, and emtricitabine/tenofovir (Truvada®) costs between 20 and 40 dollars per pill. So, a daily regimen with Truvada® costs between 7300 and 14600 USD per person per year.
- The FDA has already approved at least one generic alternative to Truvada® [30], which would lower PrEP costs.
- Reducing costs and implementing infrastructure and adherence programs that ensure maximum effectiveness are needed in order to maximize the cost-effectiveness of PrEP.
- It is reasonable to conduct a formal economic analysis in the places where this intervention is being considered, especially in places where the direct cost of the drug, or those derived from its implementation, are substantial.

What would patients and their doctors think about this intervention

- Faced with the evidence presented in this summary, most patients and physicians should lean in favor of its use.
- However, there are prejudices about the possibility that the use of PrEP would promote risky behaviors in men who have sex with men, although this has not been proven. This concern has permeated patients, and some see PrEP users as irresponsible. While this perception is probably changing rapidly, it is important to consider this factor.

Differences between this summary and other sources

- The conclusions of our summary agree with those of most of the systematic reviews identified.
- The main clinical guidelines, such as the CDC [31] and the WHO PrEP implementation tool [32] highlight that emtricitabine/tenofovir is the approved PrEP formulation and that there is insufficient evidence to support the use of tenofovir disoproxil fumarate alone as prevention.
- The USPSTF is, as of December 2017, still in the process of giving a recommendation regarding PrEP [33].


Could this evidence change in the future?

- The likelihood that the conclusions of this summary about the effectiveness of oral PrEP is modified with future evidence is low given the high certainty of the existing evidence. The conclusions about changes in risk behaviors might probably change with new evidence.
- There are randomized trials evaluating the safety of a new formulation of tenofovir (tenofovir alafenamide with emtricitabine) [34] and at least one evaluating the effectiveness of a new injectable antiretroviral used as PrEP, cabotegravir, in trans women and men who have sex with men compared to emtricitabine/tenofovir [35].
- No new trials evaluating the use of monotherapy with tenofovir disoproxil fumarate in men who have sex with men were found.
- Several systematic reviews are in process evaluating different aspects of PrEP, such as costeffectiveness [36],[37], its influence on sexual risk behaviors [38] and its effect on bone mineral density [39].



How we conducted this summary

Using automated and collaborative means, we compiled all the relevant evidence for the question of interest and we present it as a matrix of evidence.



An evidence matrix is a table that compares systematic reviews that answer the same question.

Rows represent systematic reviews, and columns show primary studies.

The boxes in green correspond to studies included in the respective revisions.

The system automatically detects new systematic reviews including any of the primary

studies in the matrix, which will be added if they actually answer the same question.

Follow the link to access the **interactive version**: <u>Oral PrEP for prevention of HIV infection in men</u> who have sex with men

Notes

The upper portion of the matrix of evidence will display a warning of "new evidence" if new systematic reviews are published after the publication of this summary. Even though the project considers the periodical update of these summaries, users are invited to comment in *Medwave* or to contact the authors through email if they find new evidence and the summary should be updated earlier.

After creating an account in Epistemonikos, users will be able to save the matrixes and to receive automated notifications any time new evidence potentially relevant for the question appears.

This article is part of the Epistemonikos Evidence Synthesis project. It is elaborated with a pre-established methodology, following rigorous methodological standards and internal peer review process. Each of these articles corresponds to a summary, denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos), whose main objective is to synthesize the body of evidence for a specific question, with a friendly format to clinical professionals. Its main resources are based on the evidence matrix of Epistemonikos and analysis of results using GRADE methodology. Further details of the methods for developing this FRISBEE are described here

(http://dx.doi.org/10.5867/medwave.2014.06.5997)

Epistemonikos foundation is a non-for-profit organization aiming to bring information closer to health decisionmakers with technology. Its main development is Epistemonikos database (<u>www.epistemonikos.org</u>).

Potential conflicts of interest

The authors do not have relevant interests to declare.



References

- 1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016 Jul;30(12):1973–83.
- Freeborn K, Portillo CJ. Does Pre-exposure prophylaxis (PrEP) for HIV prevention in men who have sex with men (MSM) change risk behavior? A systematic review. J Clin Nurs. 2017 Aug.
- 3. Jiang J, Yang X, Ye L, Zhou B, Ning C, Huang J, et al. Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e87674.
- 4. Kennedy CE, Fonner VA, World Health Organization. Pre-exposure prophylaxis for men who have sex with men: a systematic review. 2014.
- 5. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane database Syst Rev. 2012 Jul;(7):CD007189.
- Yu W, Wang L, Han N, Zhang X, Mahapatra T, Mahapatra S, et al. Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? Artif cells, nanomedicine, Biotechnol. 2016;44(1):201–8.
- Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014 Aug;66(5):530–7.
- Buchbinder SP, Glidden D V, Liu AY, McMahan V, Guanira J V, Mayer KH, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014 Jun;14(6):468–75.
- Carlo Hojilla J, Koester KA, Cohen SE, Buchbinder S, Ladzekpo D, Matheson T, et al. Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes. AIDS Behav. 2016 Jul;20(7):1461–9.
- 10.Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010 Aug;54(5):548–55.
- 11.Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec;363(27):2587–99.
- 12.Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep;14(9):820–9.
- 13.Hoff CC, Chakravarty D, Bircher AE, Campbell CK, Grisham K, Neilands TB, et al. Attitudes Towards PrEP and Anticipated Condom Use Among Concordant HIV-Negative and HIV-Discordant Male Couples. AIDS Patient Care STDS. 2015 Jul;29(7):408–17.

- 14.Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013 Apr;62(4):447–56.
- 15.Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014 Oct;210(8):1217–27.
- 16.Liu A, Glidden D V, Anderson PL, Amico KR, McMahan V, Mehrotra M, et al. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014 Dec;67(5):528–37.
- 17.Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016 Jan;176(1):75–84.
- 18.Marcus JL, Glidden D V, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8(12):e81997.
- 19.McCormack S, Dunn DT. Pragmatic open-label randomised trial of preexposure prophylaxis: The PROUD Study. In: CROI. Seattle, Washington; 2015.
- 20.McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016 Jan;387(10013):53–60.
- 21.Solomon MM, Lama JR, Glidden D V, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014 Mar;28(6):851–9.
- 22.Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015 Nov;61(10):1601–3.
- 23.Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015 Dec;373(23):2237–46.
- 24.Molina J-M, Capitant C, Charreau I. On demand PrEP with oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. In: CROI. Seattle, Washington; 2015.
- 25.Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIVuninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013 Sep;64(1):79–86.
- 26.Liu AY, Vittinghoff E, Gandhi M, Huang Y, Chillag K, Wiegand R. Validating measures of tenofovir drug exposure in a U.S. pre-exposure prophylaxis trial. In: CROI. Seattle, Washington; 2015.
- 27.Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. Sexual risk behavior among HIV-



uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr. 2013 Sep;64(1):87–94.

- 28.Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688.
- 29.Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.
- 30.Food and Drug Administration. First Generic Drug Approvals [Internet]. 2017 [cited 2017 Dec 10]. | Link
- 31. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States [Internet]. 2014. | Link |
- 32.World Health Organization. WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection [Internet]. 2017. | Link |
- 33.U.S. Preventive Services Task Force. Draft Update Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Pre-Exposure Prophylaxis [Internet]. 2017 [cited 2017 Jan 12]. | Link |
- 34.Gilead Sciences. Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men

and Are At Risk of HIV-1 Infection (DISCOVER) [Internet]. Report No.: NCT02842086. | Link |

- 35.National Institute of Allergy and Infectious Diseases. Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men [Internet]. Report No.: NCT02720094. | Link |
- 36.Murchu EO. Systematic review of the clinical effectiveness and cost-effectiveness of various dosing schedules of pre-exposure prophylaxis (PrEP) for the prevention of HIV in males who have sex with males (MSM). [Internet]. Report No.: CRD42017065937. | Link |
- 37.Thavorn K, Mishra S, Tan D, Kugathasan H, Moqueet N, McFadden D. Cost-effectiveness of HIV Pre-exposure Prophylaxis (PrEP) strategies: a methodological systematic review [Internet]. Report No.: CRD42016038440. | Link |
- 38.Traeger M, Schröder S, Doyle J, Stoové M. Effects of pre-exposure prophylaxis (PrEP) on sexual risk taking behaviour in men who have sex with men: a systematic review and meta-analysis. Report No.: CRD42017059674.
- 39.Baranek B, Wang S, Cheung A, Mishra S, Tan D. A systematic review and meta-analysis of the effect of oral tenofovir disoproxil fumarate-containing HIV preexposure prophylaxis on bone mineral density [Internet]. Report No.: CRD42017070552. | Link |

Author address: [1] Centro Evidencia UC Pontificia Universidad Católica de Chile Centro de Innovación UC Anacleto Angelini Avda.Vicuña Mackenna 4860 Macul Santiago Chile



Esta obra de Medwave está bajo una licencia Creative Commons Atribución-No Comercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.